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A B S T R A C T
Background: Misoprostol is as effective as dinoprostone for labor induction with low cost and temperature stability. Aim: This 
study designed to compare titrated misoprostol regarding its safety and efficacy with dinoprostone for induction of labor. 
Subjects and Methods: Women with a single pregnancy, above 37 weeks’ gestation, cephalic presentation, modified Bishop’s 
score <8, and not in labor with reassuring fetal heart rate, admitted for labor induction enrolled in this randomized controlled 
study. Studied women were randomized into; Group I: received oral misoprostol titrated in sterile water (200 µg tablet was 
dissolved in 200 ml sterile water [1 µg/ml]), starting dose of 20 µg misoprostol required, given every 2 h, and stopped if adequate 
contractions obtained and Group II: received vaginal dinoprostone tablet maximum two doses followed by augmentation of labor 
by oxytocin ± amniotomy if there is no uterine contractions after two doses of dinoprostone. In Group I, if the contractions were 
inadequate after two doses of oral titrated misoprostol (20 µg [20 ml]), the starting dose increased to 40 µg (40 ml), escalating 
the dose from 5 to 10 ml (45–50 µg), and 20 ml (60 µg) maximum ± amniotomy. If the uterine contractions were adequate, 
the next dose of misoprostol or dinoprostone was omitted. Statistical analysis done using Student’s t-test for quantitative 
data and Chi-square test for qualitative data. Results: Induction‑to‑delivery time was significantly longer in misoprostol than 
dinoprostone group (975 vs. 670 min, respectively), (P = 0.01). About 20.2% (21/104) of women in misoprostol group did not 
deliver vaginally within 24 h compared to 7.4% (8/108) in dinoprostone group (significant difference, P = 0.01). Augmentation 
of labor was significantly high in dinoprostone (37.96% [41/108]) compared to misoprostol group (10.6% [11/104]) (P < 0.01). 
Conclusion: Titrated misoprostol for induction of labor seems to be associated with significantly longer induction‑to‑delivery 
time, low incidence of vaginal birth within 24 h, and less need for augmentation of labor compared to vaginal dinoprostone.
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INTRODUCTION
Induction of labor defined as artificially initiating uterine 
contractions, prior to their spontaneous onset, with progressive 
cervical dilatation and subsequent delivery of the baby.[1]
Prolonged gestational age is the most common cause for 
induction of labor in obstetrics practice. Induction of labor 
may be difficult or unsuccessful with subsequent cesarean 
delivery and prostaglandins is used in obstetrics practice for 
cervical ripening before labor induction.[2,3]
Prostaglandins registered for induction of labor are 
expensive and unstable in room temperature.[4] Cervical 
ripening is associated with an increase in cyclooxygenase 
enzyme, which leads to increase local prostaglandins 
production in the cervix with subsequent more cervical 
ripening.[5]
Misoprostol is a prostaglandin E1 analog, and it is as effective 
as dinoprostone with low cost and temperature stability. 
Uterine hyperstimulation associated with misoprostol is 
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dose-dependent and related to the route of misoprostol 
administration.[6]
Previous studies concluded that misoprostol is effective as 
cervical ripening agents and reported that the challenge is 
to administer misoprostol accurately while maintaining the 
ability to discontinue the medication when needed. Recent 
coworkers utilized a misoprostol delivery system that 
controls misoprostol release and rapid removal.[7,8]
Most researchers used misoprostol vaginally, while oral 
administration of misoprostol is easier, more convenient, 
and has several advantages. Recorded peak of oral 
misoprostol was 227 pg/ml after 34 min compared with 
165 pg/ml after 80 min for vaginal misoprostol, and oral 
route of misoprostol is characterized by short half-life.[9]
This study designed to compare titrated misoprostol 
regarding its safety and efficacy with dinoprostone for 
induction of labor.
SUBJECTS AND METHODS
This randomized controlled study conducted from June 
2013 to August 2014 after approval of the Institute Ethical 
Research Committee of Ain Shams University, Cairo, 
Egypt. After thorough explanation, women included in 
this study had to sign written consent explaining the 
purpose and procedures of this study. Women with a 
single pregnancy, >37 weeks’ gestation (from the 1st day 
of last menses and confirmed by ultrasound done at 
20 weeks’ gestation), cephalic presentation, modified 
Bishop’s score <8, and not in labor with reassuring 
fetal heart rate by cardiotocography (CTG) (basal fetal 
heart rate 120–160 beats/min, with good variability and 
accelerations of fetal heart beats 15 beats/min in response 
to fetal movements without decelerations) for 20–30 min 
on the day of induction admitted for labor induction 
enrolled in this study.
Women with premature rupture of fetal membranes, 
previous uterine scar, fetal malpresentation, multiple 
pregnancies, significant antepartum hemorrhage, 
uncontrolled diabetes, severe preeclampsia or eclampsia, 
and women who have contraindications to receive the 
induction medications (allergy, history of severe asthma) 
excluded from this study. Studied women were randomized 
into; Group I: 104 women included and received oral 200 µg 
misoprostol in 200 ml water titrated over 12 h and Group II: 
108 women included and received vaginal dinoprostone 
tablet (3 mg) maximum two doses.
Randomization performed using a computer-generated 
randomization system. A plan of interventions was 
sealed in closed envelopes, numbered in accordance 
with the randomization tables, and opened before the 
induction process. Packing, sealing, and numbering were 
all performed by two independent doctors other than the 
investigator.
Women included in this study subjected to thorough history, 
general and local vaginal examination with evaluation of 
modified Bishop’s score.
Studied women monitored by the external CTG continuously 
through labor induction process to assess uterine 
contractions and fetal heart rates and examined vaginally 
4 hourly to assess the progress of induction process.
In Group I: Misoprostol available tablets is 200 µg tablet 
misoprostol (Sigma Pharmaceutical Industries, Cairo, 
Egypt) was dissolved in 200 ml sterile water (1 µg/ml), 
shaking the solution well before each administration. 
A prepared solution made up freshly for each woman 
admitted for induction of labor and the same bottle used 
till finished (maximum 12 h). For induction of labor, a 
starting dose of 20 µg misoprostol required, given every 
2 h, and stopped if adequate contractions obtained (three 
contractions in 10 min each lasting 40–60 s with progressive 
cervical changes). If the contractions were inadequate after 
two doses of oral titrated misoprostol (20 µg [20 ml]), 
the starting dose increased to 40 µg (40 ml), escalating 
the dose from 5 to 10 ml (45–50 µg), and 20 ml (60 µg) 
maximum ± amniotomy.
In Group II: Dinoprostone 3 mg tablet (Alexandria 
Pharmaceuticals Co. Cairo, Egypt) was inserted in 
vaginal fornix and repeated 6 hourly if contractions were 
inadequate (maximum two doses). If the uterine contractions 
were inadequate after two doses of dinoprostone, 
augmentation of the active phase of labor attempted by 
oxytocin infusion ± amniotomy.
If the uterine contractions were adequate, the next dose of 
misoprostol or dinoprostone was omitted.
Primary outcome measures; induction delivery time (time 
from the start of induction medication until delivery). 
Secondary outcomes measure the duration of the first 
and second stages of labor, maternal complications, side 
effects of induction agents, mode of delivery, and neonatal 
outcome.
Sample size justification
The required sample size was calculated using G* power 
software version 3.17 for sample size calculation (*Heinrich 
Heine Universität; Düsseldorf; Germany), setting α-error 
probability at 0.05, power (1-β error probability) at 0.95% 
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and effective sample size (w) at 0.3, and data from previous 
study,[8] which concluded that vaginal misoprostol in 
doses above 25 µg four hourly was more effective than 
conventional methods of labor induction but with more 
uterine hyperstimulation and lower misoprostol doses 
were similar to conventional methods in effectiveness 
and risks. The effective size (w) was calculated as follows:
w N= /2χ , where 2 is the Chi-square test and N is the 
total sample size.
Statistical analysis
Statistical analysis was done using Statistical Package 
for Social Sciences (SPSS) version 20 (Chicago, IL, USA). 
Data were presented as mean and standard deviation if 
it was numerical data and number (n) and percentage (%) 
if it was categorical data. Student’s t-test for quantitative 
data analysis and Chi-square was used for qualitative data 
analysis.
RESULTS
Two hundred and twenty-three women recruited in 
the beginning of this study and it was completed with 
212 women. One hundred and four women in Group 1 or 
titrated oral misoprostol (seven women dropped due to; 
missed notes, spontaneous rupture of membranes, and 
spontaneous onset of labor) and 108 women in Group II or 
vaginal dinoprostone tablet (four women dropped due to; 
spontaneous rupture of membranes and spontaneous onset 
of labor) [Figure 1].
Maternal age, gestational age, parity, body mass index, 
and indications of induction of labor were similar in 
both studied groups with no statistical difference. 
Moreover, there was no difference between two studied 
groups regarding; initial modified Bishop’s score 
assessment [Table 1].
The induction-to-onset of contraction interval and 
the whole induction-to-delivery time were shorter in 
Group II (vaginal dinoprostone group) compared to 
Group I (titrated oral misoprostol), while the active 
phase of the first stage and the second stage of labor 
were significantly shorter in Group I compared to 
Group II [Table 2].
Need for epidural analgesia and rate of uterine 
hyperstimulation during induction of labor were similar in 
the two studied groups with no statistical difference.
Augmentation of labor was significantly high in 
dinoprostone (37.96% [41/108]) compared to misoprostol 
group (10.6% [11/104]) (P < 0.01). Mode of delivery, 
rate of operative vaginal delivery for intrapartum fetal 
compromise or protracted second stage of labor and rate 
of cesarean delivery for intrapartum fetal compromise, and 
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Figure 1: Flow diagram of the studied women
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without statistical difference between two studied groups. 
Complications of inductions and side effects of induction 
agents were similar without statistical difference between 
two studied groups [Table 3].
Fetal birth weight, 5 min Apgar score, and rate of 
Neonatal Intensive Care Unit (NICU) admission were 
similar without statistical difference between two studied 
groups [Table 4].
Table 1: Demographic data, indication of induction of labor, and initial modified Bishop’s score in both studied groups
Variables Group I (titrated oral misoprostol) 
(n=104)




Mean (SD) 26.13 (5.6) 26.5 (5.2) 0.2*
Parity
Median (IQR) 0 (0‑2) 0 (0‑2) 1**
Parity
Nulliparous (n and %) 52 (50) 60 (55.6) 0.6**
Multiparous (n and %) 52 (50) 48 (44.4) 1**
BMI (kg/m2)
Mean (SD) 31.47 (3.07) 32.21 (3.39) 0.9*
Gestational age (weeks)
Mean (SD) 40.58 (1.18) 40.61 (1.2) 0.5*
Indications of induction of labor decreased
Diminished fetal movements (n and %) 36 (34.6) 46 (42.6) 0.4**
Prolonged pregnancy (n and %) 41 (39.4) 40 (37) 0.8**
Hypertensive disorders (n and %) 15 (14.4) 13 (12) 0.6**
Diabetes mellitus (n and %) 12 (11.5) 9 (8.3) 0.4**
Initial Bishop’s score
Median (IQR) 6 (5-7) 6 (5-7) 1**
*Analysis using independent Student’s t-test, **Analysis using Chi-square test. n and %=Number and percentage, SD=Standard deviation, IQR=Interquartile range, BMI=Body mass index, FHR=Fetal 
heart rate
Table 2: Duration of phases of labor, induction‑to‑onset of contractions, and induction to delivery intervals in both studied groups
Variables Group I (titrated oral misoprostol) 
(n=104)
Group II (vaginal dinoprostone) 
(n=108)
P, significance
Induction-to-onset of contractions interval (min), 
median (IQR)
480 (330‑720) 330 (260‑435) <0.01
Duration of latent phase of the first stage of labor (min), 
median (IQR)
360 (300‑420) 330 (240‑420) 0.4
Duration of active phase of the first stage of labor (min), 
median (IQR)
90 (60‑180) 135 (97.5-232.5) 0.05
Duration of the first stage of labor (min), median (IQR) 480 (360‑800) 464 (360‑592.5) 0.6
Duration of the second stage of labor (min), median (IQR) 30 (15‑50) 60 (40‑107.5) 0.01
Induction-to-delivery interval (min), median (IQR) 975 (760‑1405) 760 (720‑1095) 0.01
Analysis using Chi-square test. IQR=Interquartile range
Table 3: Use of epidural analgesia, augmentation of labor and rate of uterine hyperstimulation, mode of delivery, and 
complications of induction of labor in both studied groups
Variables Group I (titrated oral misoprostol) 
(n=104) (%)
Group II (vaginal dinoprostone) (n=108) (%) P, significance
Use of epidural analgesia 7 (6.7) 4 (3.7) 0.3
Artificial rupture of the membranes 94 (90.4) 102 (94.4) 0.8
Need for augmentation of labor 11 (10.6) 41 (37.96) <0.01
Uterine hyperstimulation
With FHR changes 1 (1.0) 1 (0.9) 1
Without FHR changes 1 (1.0) 1 (0.9) 1
Mode of delivery
Vaginal delivery 101 (97.1) 102 (94.4) 0.3
Cesarean delivery 3 (2.9) 6 (5.6) 0
Forceps-assisted delivery for intrapartum 
fetal compromise
1 (1) 1 (0.9) 1
Forceps-assisted delivery for protracted 
second stage
2 (1.9) 1 (0.9) 0.5
Maternal side effects
Shivering 4 (3.8) 0 (0) 0.1
Diarrhea 6 (5.8) 3 (2.8) 0.3
Pyrexia 3 (2.9) 3 (2.8) 1
Maternal complications
Retained placenta 1 (1) 1 (0.9) 1
Atonic postpartum hemorrhage 1 (1) 0 (0) 0.2
Data presented as number and percentage. *Analysis using Chi-square test. FHR=Fetal heart rate
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DISCUSSION
Two hundred and twelve women were included in this 
study to compare titrated misoprostol regarding its 
safety and efficacy with dinoprostone for induction of 
labor; 52.8% of studied women were nulliparous and 
47.2% were multiparous.
While, indications of labor induction were prolonged 
pregnancy (50.6%), hypertensive disorders (29.4%), 
diminished fetal movements (15.6%), and 4.4% for other 
causes (4.4%) in Patil et al. study.[10]
In this study, the induction-to-delivery time was significantly 
longer in misoprostol group versus dinoprostone group.
Dodd et al. compared titrated misoprostol versus vaginal 
dinoprostone for labor induction, and they found that 
the induction-to-delivery time was significantly longer in 
titrated oral misoprostol versus dinoprostone group (21.2 h 
vs. 18.4 h, respectively).[11]
Hofmeyr et al. randomized 695 women to receive either 
titrated misoprostol solution or dinoprostone 2 mg, for labor 
induction, and they found that the induction-to-delivery 
time was longer in misoprostol versus dinoprostone 
group (17.1 vs. 14.25 h, respectively).[6]
On the other hand, Patil et al.[10] found that the 
induction-to-delivery time shorter in oral misoprostol 
group (11.68 ± 4.49 h) compared to intracervical 
dinoprostone (14.83 ± 7.08 h).
This difference between this study and Patil et al.[10] study 
regarding induction-to-delivery time is due to the different dose 
and route regimens of both oral misoprostol and dinoprostone 
used in this study compared to Patil et al. study.[10]
In this study, 20.2% of women in misoprostol group did 
not deliver vaginally within 24 h compared to 7.4% in 
dinoprostone group.
Although Sheela et al. found that 35% women in misoprostol 
group did not deliver vaginally within 24 h compared to 
13% in the vaginal dinoprostone group (high significant 
difference).[12]
Hofemyr et al. found that 38% of women in misoprostol group 
did not deliver vaginally within 24 h compared to 36% in the 
vaginal dinoprostone group (no significant difference).[6]
In addition, Dällenbach et al. found no significant difference 
in the percentage of women who did not deliver vaginally 
within 24 h between misoprostol group compared to 
dinoprostone group (44% vs. 38%, respectively).[13]
Prolonged labor was observed in this study in titrated 
oral misoprostol group, while labor duration was same in 
misoprostol and dinoprostone groups in Hofemyr et al.[6] 
and Dällenbach et al.[13] studies. This may be due to wide 
scale usage of epidural analgesia in other studies, which 
causes prolonged labor and prolonged second stage.[14]
Percentage of cesarean section was similar with no difference 
between two studied groups; 2.9% in oral misoprostol group 
versus 5.6% in vaginal dinoprostone group. Cesarean sections 
were done in oral misoprostol group due to fetal distress (1.9%) 
and failed induction (1% [1/104]), while cesarean sections were 
done in vaginal dinoprostone group due to failed induction 
(3.7%), protracted labor (0.9%), and fetal distress (0.9%).
Patil et al. found no significant difference between oral 
misoprostol group and intracervical Dinoprostone group 
regarding the percentage of cesarean section; however, the 
indications for cesarean section in the two studied groups 
were different.[10]
Cesarean sections indicated in oral misoprostol group 
due to fetal distress, meconium stained liquor, hypertonic 
contractions not responding to pharmacologic drugs, and 
failure to progress, while cesarean sections indicated in 
vaginal dinoprostone group due to failed induction, fetal 
distress, and meconium stained liquor.[10]
Hofemyr et al. found that the rate of cesarean section 
was less in titrated oral misoprostol group (16%) versus 
vaginal dinoprostone group (20%), and this difference was 
statistically insignificant.[6]
Table 4: Fetal birth weight, 5 min Apgar score, and rate of Neonatal Intensive Care Unit admission in both studied groups
Variables Group I (titrated oral misoprostol) 
(n=104)
Group II (vaginal dinoprostone) (n=108) P, significance
Birth weight (g)
Mean (SD) 3231.7 (445.3) 3151.9 (461.9) 0.6*
5-min apgar score <7 (n and %) 5 (4.8) 4 (3.7) 0.9**
NICU admission
TTN (n and %) 1 (1) 2 (1.9) 0.9**
Congenital pneumonia (n and %) 1 (1) 0 (0) 0.9**
*Analysis using independent Student’s t-test. **Analysis using Chi-square test. NICU=Neonatal Intensive Care Unit, TTN=Transient tachypnea of the newborn, n and %=Number and percentage
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Alfirevic et al. concluded that oral misoprostol as an 
induction agent is effective in achieving a vaginal birth. 
It is more effective than placebo, as effective as vaginal 
misoprostol and results in fewer cesarean sections than 
vaginal dinoprostone or oxytocin.[15]
In addition, Alfirevic et al. concluded that the evidence 
supported the use of oral misoprostol over vaginal 
regimens and suggested a dose of oral misoprostol should 
be 20–25 mcg in solution.[15]
Aalami-Harandi et al. concluded that misoprostol is a safe 
and effective drug with low complications for the induction 
of labor and cesarean sections are less frequently indicated 
with misoprostol as compared to oxytocin.[16]
In addition, Ho et al. concluded that labor augmentation with 
titrated oral misoprostol or intravenous oxytocin resulted in 
similar rates of vaginal delivery within 12 and 24 h.[17]
Epidural analgesia used in 6.7% of women in oral misoprostol 
group compared to 3.7% in vaginal dinoprostone group in 
this study (no significant difference).
The need for augmentation of labor was significantly high in 
vaginal dinoprostone (37.96%) compared to oral misoprostol 
group (10.6%).
Hofemyr et al. found that 30% of women in misoprostol 
group managed by artificial rupture of membranes versus 
33% in vaginal dinoprostone group (this may be attributed to 
the inclusion of women with rupture of membranes in their 
study).[6] In addition, Hofemyr et al. found that augmentation 
of labor was needed in 33% of women in vaginal dinoprostone 
group compared to 17% in titrated oral misoprostol group.[6]
Uterine hyperstimulation recorded in 0.94% of both studied 
groups and one case (0.47%) of them was associated with 
fetal heart rate changes with no significant difference 
between two studied groups.
Hofemyr et al. found that 4% of uterine hyperstimulation 
with fetal heart rate changes was recorded in misoprostol 
group versus 3% in vaginal dinoprostone group with no 
significant difference.[6]
Dodd et al. found that 1.6% of uterine hyperstimulation with 
fetal heart rate changes recorded in dinoprostone group 
compared to 0.8% in misoprostol group.[11]
Randomized trials comparing titrated oral misoprostol 
with placebo, other interventions (oxytocin, other 
prostaglandins), or no treatment for labor augmentation 
conducted by Vogel et al.[18]
Vogel et al. concluded that low-dose titrated misoprostol 
may offer a better alternative to an uncontrolled oxytocin 
infusion to avoid hyperstimulation.[18]
In addition, Souza et al. concluded that the oral solution 
of misoprostol was effective and safe for the induction of 
labor. However, further randomized controlled trials are 
needed to compare this new formulation with misoprostol 
administered by the vaginal route.[19]
Souza et al. in another study concluded that a titrated oral 
misoprostol solution was as effective and safe for labor 
induction as vaginal misoprostol tablets.[20]
Birth weight, 5 min Apgar score <7, and rate of NICU 
admission were similar with no significant difference 
between two studied groups.
Hofemyr et al. found that the 5 min Apgar score <7 was 
3% in misoprostol group versus 4% in Dinoprostone group 
and 2% NICU admission in misoprostol group versus 3% in 
dinoprostone group.[6]
Zvandasara et al. concluded that titrated oral misoprostol 
suspension is as effective and safe as vaginal misoprostol 
for induction of labor even in poor resource countries 
where intrapartum monitoring is inadequate.[21]
Cheng et al. concluded that titrated oral misoprostol 
solution is a promising method of labor induction for both 
nulliparous and multiparous women.[22]
The strength of this study is coming from the comparative 
nature of the study and proper statistical analysis, while 
women refused to participate in this study and technical 
difficulties preparing placebo for both misoprostol solution 
and vaginal dinoprostone were limitations faced during 
conduction of this study.
Low titration dose of misoprostol used in this study explains 
the vaginal birth achieved after 24 h in titrated misoprostol 
group. Further clinical studies are needed to reach proper 
titration dose for oral misoprostol and to encourage the 
availability of this dose in markets for safe use in labor 
induction.
CONCLUSION
Titrated misoprostol for induction of labor seems to be 
associated with significantly longer induction-to-delivery 
time, low incidence of vaginal birth within 24 h, and 
less need for augmentation of labor compared to vaginal 
dinoprostone.
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